folder

N-myristoyltransferase inhibition is synthetic lethal in MYC-deregulated cancers

Authors

  • G.A. Lueg
  • M. Faronato
  • A. Gorelik
  • A.G. Grocin
  • E. Caamano-Gutierrez
  • F. Falciani
  • R. Solari
  • R. Carr
  • A.S. Bell
  • E. Bartlett
  • J.A. Hutton
  • M. Llorian-Sopena
  • P. Chakravarty
  • B. Brzezicha
  • M. Janz
  • M.J. Garnett
  • D.P. Calado
  • E.W. Tate

Journal

  • bioRxiv

Citation

  • bioRxiv

Abstract

  • Human N-myristoyltransferases (NMTs) catalyze N-terminal protein myristoylation, a modification regulating membrane trafficking and interactions of >100 proteins. NMT is a promising target in cancer, but a mechanistic rationale for targeted therapy remains poorly defined. Here, large-scale cancer cell line screens against a panel of NMT inhibitors (NMTi) were combined with systems-level analyses to reveal that NMTi is synthetic lethal with deregulated MYC. Synthetic lethality is mediated by post-transcriptional failure in mitochondrial respiratory complex I protein synthesis concurrent with loss of myristoylation and degradation of complex I assembly factor NDUFAF4, followed by mitochondrial dysfunction specifically in MYC-deregulated cancer cells. NMTi eliminated MYC-deregulated tumors in vivo without overt toxicity, providing a new paradigm in which targeting a constitutive co-translational protein modification is synthetically lethal in MYC-deregulated cancers. ONE-SENTENCE SUMMARY: N-myristoyltransferase inhibition leads to post-transcriptional complex I failure and cell death in MYC-deregulated cancers.


DOI

doi:10.1101/2021.03.20.436222